Category Archives: Regenerative Medicine

THE WOODLANDS, TX -- 3R Regenerative Repair and Relief (3R) today announced Edward Nash, M.D, has been voted 2021 Best Pain Management Doctor and Best Regenerative Medicine Doctor in The Woodlands by Living Magazines 9th Annual Best Of Readers Choice Awards!

Dr. Nash, an MD and Physiatrist who specializes in pain management and regenerative medicine, is the owner of Progressive Pain and Rehabilitation and a partner at 3R Regenerative Repair and Relief in The Woodlands, just outside of Houston, Texas.

Dr. Nash was selected Best Pain Management Doctor and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine readers who cast their votes in the annual Best Of competition in 150 categories that celebrate the best businesses, organizations, and people in dining, retail, entertainment, healthcare and home & garden in Houston Metro Area communities.

Its really an honor to be selected by the community and Living Magazine as a Best Of Award winner in two categories, said Dr. Nash. Im proud to be recognized among some of the best doctors and healthcare facilities in the Houston Area and passionate about raising the bar for safe, innovative pain management and healthcare solutions in our community.

Dr. Nash is a Houston native and a Diplomate of the American Board of Physical Medicine and Rehabilitation. He has been practicing medicine since earning his doctorate degree from the University of Texas-Houston in 2002. After completion of an internship in Internal Medicine from the University of Texas-Houston, he received specialty training from the prestigious allied Baylor College of Medicine and University of Texas-Houston Physical Medicine and Rehabilitation Department.

Following residency training, Dr. Nash joined KSF Orthopedic Center, where he became a partner and worked for 12 years. In 2018, he started Progressive Pain and Rehabilitation in The Woodlands to provide non-surgical advanced pain management solutions and custom treatment for his patients.

That same year, Dr. Nash partnered with Doctor Jeffery Pruski, D.C., to form 3R Regenerative Repair and Relief in The Woodlands to provide a combination of non-invasive biologic therapies, physical therapy and chiropractic care to patients suffering from back and joint pain, arthritis, neuropathy and sports injuries.

Doctors Nash and Pruski were some of the first to successfully use regenerative medicine, each individually, since 2014. The pair have helped hundreds of professional athletes and patients of all ages suffering from chronic pain, neck and back injuries, arthritis and degenerative conditions live healthier, pain-free lives.

Dr. Nash is a member of the American Academy of PMR, Texas Medical Association, Harris County Medical Society, American Academy of Regenerative Medicine, American Academy of Pain Medicine and the American Society of Interventional Pain. He has earned a number of prestigious awards over the course of his career including Texas Super Doctors (2015, 2016, 2017, 2018, 2019, 2020, 2021), Texas Rising Stars (2012, 2013, 2014), Compassionate Doctor Recognition (2010, 2011, 2015, 2016), Top 10 Doctor Houston 2014, Castle Connollys Top Doctors 2013, Patients Choice Award 2010, Doctors Choice 2011 and Living Magazines Best Regenerative Medicine Doctor in The Woodlands Readers Choice in 2020.

Visit link:
Dr. Edward Nash Named Best Pain Management and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine - Woodlands Online

The updated report on theRegenerative Medicine marketgives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the administration of the key market companies and their revenue-generating business strategies adopted by them to drive sustainable business. TheService industryreport further enlists the market shortcomings, stability, growth drivers, restraining factors, opportunities for the projected timeframe.

Get Sample Report with Latest Industry Trends Analysis:

https://www.a2zmarketresearch.com/sample?reportId=538944

The top companies in this report include:

ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter.

The Global Regenerative Medicine market is expected to register a notable market expansion ofXX%during the review period owing to the largest market value in 2019. The market study provides a measure of the effectiveness of the product, real-time Regenerative Medicine market scenario, along custom ease. The study further offers market analysis, strategies and planning, R & D landscape, target audience management, market potential, due diligence, and competitive landscape.

Market Segmentation

Segment By Type

Mono Avalanche AirbagsDual Avalanche Airbags

Segment By Application

SkiingClimbingHiking

Scope of the report:

A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Regenerative Medicine market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Regenerative Medicine research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

The Regenerative Medicine report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2021 to 2027. To leverage business owners, gain a thorough understanding of the current momentum, the Regenerative Medicine research taps hard to find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Regenerative Medicine market offers knowledge of what is in store for the business owners in the upcoming years.

Request For Customized Report:

https://www.a2zmarketresearch.com/enquiry?reportId=538944

Geographic analysis

The global Regenerative Medicine market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Regenerative Medicine Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Regenerative Medicine refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Regenerative Medicine drinks market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Regenerative Medicine makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Regenerative Medicine inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report:

https://www.a2zmarketresearch.com/buy?reportId=538944

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Diyhomeimprovement Market to Witness Stunning Growth Sears Holding, Home Depot, HORNBACH Baumarkt, Les Mousquetaires, Kingfisher

See the rest here:
Regenerative Medicine Market to witness Robust Expansion by 2027 | ABS Protection GmbH, Mammut, Clarus Corporation - The Market Writeuo - The Market...

How are iPSC companies growing and how can they strategize to make use of the growing opportunities in the market?

LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- According to The Business Research Companys research report on the iPSC market, North America is the largest region in the induced pluripotent stem cell market, accounting for 49.8% of the total in 2020. It was followed by Western Europe, and then the other regions. Going forward, the fastest-growing regions in the induced pluripotent stem cells market will be Africa and Asia- Pacific, where growth will be at CAGRs of 15.7% and 15.4% respectively. These will be followed by South America, and the Middle East where the markets are expected to grow at CAGRs of 13.7% and 12.4% respectively.

The induced pluripotent stem cell (iPSC) market is highly fragmented, with a large number of iPSC companies constituting the market. The top ten competitors in the market made up to 26% of the total market in 2020. This is mainly due to the high growth potential of the market that is attracting new players.

Major induced pluripotent stem cell companies include Fujifilm Holding Corporation, Thermo Fisher Scientific Inc Takara Bio Inc., ViaCyte, and Fate Therapeutics. Fujifilm Holding Corporation was the largest competitor with 10.266% of the market, followed by Thermo Fisher Scientific Inc. with 8.209%, Takara Bio Inc. with 3.943%, ViaCyte with 1.192%, Fate Therapeutics with 0.707%, Horizon Discovery Group with 0.675%, Ncardia with 0.540%, StemCells with 0.337%, Cynata Therapeutics with 0.332% and Cell Applications, Inc. with 0.027%

The Business Research Companys report titled Induced Pluripotent Stem Cell (iPSC) Market By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic, Others), By Application (Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Gene & Cell Therapy), By End-User (Hospitals, Research Laboratories) And By Region, Opportunities And Strategies Global Forecast To 2030covers major iPSC companies, iPSC market share by company, iPSC manufacturers, iPSC market size, and iPSC market forecasts. The report also covers the global iPSC market and its segments.

Story continues

Request For A Sample Of The Global Induced Pluripotent Stem Cell (iPSC) Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5197&type=smp

Fujifilm Holding Corporation's (CDI) growth strategy is focused on expanding its business globally by developing autologous cell transplantation clinical therapies. For instance, in March 2019, FUJIFILM Corporation and Tokyo Medical and Dental University completed a patent licensing deal on a technology to transplant autologous mesenchymal stem cells targeting meniscus injury. Based on this agreement, Fujifilm will obtain from Tokyo Medical and Dental University (TMDU) the sole right to develop, produce, and commercialize, throughout the world, regenerative medical products that make use of synovial membrane stem cells, catalyzed through this technology. Tokyo Medical and Dental University (TMDU), in turn, will receive a direct payment, development milestone recompense, and royalty on sales from Fujifilm.

To take advantage of the opportunities available in the market, The Business Research Company recommends the induced pluripotent and stem cell companies to focus on the acquisitions of mid-size and small companies which are technologically advanced to help increase production capacity and expand product portfolio, focus on securing long-term supply contracts with significant healthcare institutions to provide the patients with quality products.

IPSC companies should consider offering value-based pricing for their induced pluripotent stem cells, as stakeholders would want to evaluate both the short- and long-term benefits of the products value, while hospitals and surgeons focus on the quality and features of the system and after-sales services. Companies should expand their business in emerging markets to increase awareness in emerging markets which results in increasing demand for induced pluripotent stem cells, among other strategies.

Induced Pluripotent Stem Cell (iPSC) Market By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic, Others), By Application (Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Gene & Cell Therapy), By End-User (Hospitals, Research Laboratories) And By Region, Opportunities And Strategies Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, segments and geographies, trends, drivers, restraints, leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Cell And Gene Therapy Market By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Neurological Disorders, Others) And By Region, Opportunities And Strategies Global Forecast To 2030

Stem Cell Global Market Report 2021: COVID-19 Growth And Change To 2030

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

The rest is here:
North America Accounts For Half Of The Global Induced Pluripotent Stem Cell (iPSC) Market According To TBRCs Regional And Competitive Landscape...

TheHuman Genome Project,a large-scale international effort to determine the complete DNA sequence that defines the human body, took more than 12 years to complete and involved thousands of researchers.

Now,a similar effort is underway to map each of the trillions of cells in the human body.

The Human Cell Atlas(HCA) would be acomprehensive map of cells that has the potential to rapidly advance the understanding of human health and the diagnosis, monitoring and treatment of disease, according to Gary Bader,a computational biologist and professor at the University of Torontos Donnelly Centre for Cellular and Biomolecular Research and the department of molecular genetics in the Temerty Faculty of Medicine.

This project will likely be larger than the Human Genome Project, and it requires a massive international effort. No single individual or institute could do this on their own, he says. Its multi-disciplinary in nature, and pulls in people from genomics and technology development, basic biology, clinical research, computational biology and ethics.

We encourage participation from all countries and relevant scientific communities.

Bader, who is on the organizing committee for HCA, is helping to co-ordinatea scientific meeting of the HCA from Aug. 25 to 27. The meeting will focus on human development and pediatrics, mapping the body from conception to adolescence. Medicine by Design is a lead sponsor of the meeting, along with theChan Zuckerberg Initiativeand others.

Bader says the August meeting will bring together groups of people who are working on critical questions about cell types and states during human development.

Were aiming to deliver a highly interactive meeting that will provide plenty of opportunities for virtual face-to-face interaction in breakout discussion sessions, Bader says. A silver lining of having the meeting online instead of in-person, as was originally planned, is that there are no space restrictions. It can be open to anyone who wants to attend. Also, there are no travel costs for attendees, and we are able to offer registration free of charge.

Session topics will include: understanding cellular decision-making during development;lineage tracing; clonal evolution; tagging and its applications;and developmental origins of health outcomes over a lifespan. There will also be a session on regenerative medicine, led byGuoji GuoandJason Rock, focusing on how developmental and pediatric single cell atlas data can shed light on tissue aging and repair processes.

Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. Regenerative medicine can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem-cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts.

There is strong evidence that well have to really understand development to live up to regenerative medicines key aims, Bader says. There are questions we dont know the answer tofor example, why do children heal better than adults? These answers are essential for researchers who are developing stem cell therapies or ways to encourage self-repair in the body.

The HCA group is mapping 14 organ systems, each organized into its own bio network. For instance, the gut, heart and kidney each have their own bio network, comprisingresearchers that focus on that specific system. Bader is part of the liver bio network.

Bader, along with the Temerty Faculty of Medicine Associate ProfessorSonya MacParlandand ProfessorIan McGilvray a scientist,and surgeon and senior scientist, respectively,at University Health Network (UHN) are part of a Medicine by Design collaborative research team that, in 2018,created the firstmap of human liver cells at the molecular level. They are currently part of the large, Medicine by Design-funded team projectstudying how to harness the livers power to regenerate.

The liver map represents the first time a human organ has been charted at the single-cell level. It illuminated the basic biology of the liver in ways that could eventually increase the success of transplant surgery and enable powerful regenerative medicine treatments for liver disease such as regenerating the liver with stem cells.

This is a tool that can be used by researchers who are developing cells in the lab. For instance, a U of T and UHN teamrecently published work that showed they can develop functional blood vessel cells found in the liver. This drew on our liver map work, which provided a benchmark for those researchers to compare their cells with adult human liver cells, says Bader. HCA continues to expand this work for example in pediatricsand it will become a fundamental resource for regenerative medicine researchers.

Medicine by Design is sponsoring the HCA meeting in August because its an opportunity to engage with the international effort on human cell mapping, which creates new scientific collaborations for the Medicine by Design community.

Moreover, the HCA informs new directions in regenerative medicine research, says Michael Sefton, executive director of Medicine by Design and aUniversity Professorin the department of chemical engineering and applied chemistry in the Faculty of Applied Science & Engineering and theInstitute of Biomedical Engineering.

This international event will connect fields and people that traditionally dont work together, says Sefton, whose lab is located at the Donnelly Centre for Cellular and Biomolecular Research. A massive collaborative undertaking is whats necessary to bring HCA to fruition, and Medicine by Design is proud to support this effort. We cant overstate how much the HCA project could advance and transform regenerative medicine.

Bader says in addition to the opportunities for scientific learning, the event could have other benefits for attendees.

One of the advantages to attending the HCA meeting is the opportunity to network and potentially find out about funding opportunities one might not be aware of otherwise. Its a great opportunity for researchers to connect beyond their local collaborations.

Funded by a $114-million grant from theCanada First Research Excellence Fund, Medicine by Design brings together more than 150 principal investigators at U of T and its partner hospitals to advance regenerative medicine discoveries.

Original post:
U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT

New study shows advanced treatment (AT) for management of LEDUs among Medicare beneficiaries is associated with significant reductions in major and minor amputation, emergency department (ED) use, and hospital readmissions vs. LEDUs managed without AT (NAT)

MARIETTA, Ga., Aug. 17, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced publication of its peer-reviewed study in the Journal of Wound Care (JWC), addressing the observed impact of Advanced Treatment (AT) using all high-cost skin substitute products in lower extremity diabetic ulcers (LEDUs) based on data from the Medicare Limited Dataset (October 1, 2015 through October 2, 2018). The study assessed outcome in patients receiving AT with all high-cost skin substitute products, as designated by the Centers for Medicare and Medicaid Services (CMS), for LEDUs versus No Advanced Treatment (NAT), and found that AT use could lead to a 42% reduction in major and minor amputations and all related costs, compared to NAT. Further, the study highlights preferable outcomes when AT follows parameters for use (FPFU), underscoring the importance of early treatment with regular intervals and well-defined treatment guidelines.

The data derived from this study are important for a number of reasons, noted Dr. David G. Armstrong, Professor of Surgery and Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at the Keck School of Medicine of the University of Southern California. Most notably, it is the first, to our knowledge, to broadly evaluate the parameters for use and associated observed impact of these advanced treatments in the wound care space. The substantial reduction, not only in amputation, but also in hospital readmission rates and visits to the emergency room suggests that our patients may be able to live more hospital-free and activity-rich days when we focus on getting to wound closure.

Story continues

In 2018, an estimated three million Americans suffered from diabetic foot ulcers (DFUs) a type of LEDU. Among patients with DFUs, more than half will develop an infection. Up to 20% of infected DFUs require major or minor amputations.

Understanding the health outcome and financial implications of different courses of treatment is essential to improving patient health and reducing cost burden to providers, patients, families, payors, and the healthcare system overall, said Dr. William Tettelbach, a lead author of the study and MIMEDX Principal Medical Officer, Medical Affairs. These data demonstrate the significant beneficial impact of AT with all high-cost skin substitute products for difficult-to-heal LEDUs, and the additional benefit of treating quickly and regularly with AT.

In addition to the physical and emotional impact on patients and caregivers, DFUs create significant economic burden, accounting for up to $4.5 billion in Medicare spending and up to $18.7 billion when the cost of infection management is included. In 2014, Medicare spending for the treatment of DFUs was an estimated $6.218.7 billion. The annual payor burden of DFU treatment ranged from $9.113.2 billion, in large part due to increased hospitalizations, home healthcare, emergency department visits, and outpatient or physician office visits.

Reducing major and minor amputations has a long-term effect on ongoing health costs, evidenced by 2010 estimates of $60,000 per patient amputation, with care costs in the year following an amputation of $44,200. The longer a DFU remains open, the greater the risk for infection, osteomyelitis, and amputation. In patients with diabetes, 85% of lower-extremity amputations are preceded by a non-healing DFU and the studys findings indicate that 42% of these amputations may be preventable.

The immediate physical and economic toll on people with diabetic lower extremity complications, including amputations, have been correlated to an increased five-year mortality rate. While these costs were not examined in this study, their inclusion could extend the economic and quality of life benefits gained by using AT.

Timothy R. Wright, MIMEDX Chief Executive Officer, commented, As a company dedicated to advancing scientific and health economic research that informs and improves patient care and outcomes, we see these analyses as providing crucial validation that advanced treatment can reduce the suffering and expenses caused by chronic LEDUs. Future research must build upon these findings and inform better treatment guidelines and reimbursement policies, so that together, we raise the standard of care for patients with LEDUs.

About MIMEDX

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit http://www.mimedx.com.

Contacts

Investors:Jack HowarthInvestor Relations404.360.5681jhowarth@mimedx.com

Media:Hilary Dixon Corporate & Strategic Communications 770.651.9307 hdixon@mimedx.com

Read more from the original source:
Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin...

Catriona Jamieson, MD, PhD, professor of medicine, Division of Hematology-Oncology, deputy director, Koman Family Presidential Endowed Chair in Cancer Research, chief, Division of Regenerative Medicine, deputy director, Sanford Stem Cell Clinical Center, co-leader, Hematologic Malignancies Program, director, Stem Cell Research, UC San Diego Moores Cancer Center, discusses the importance of treating patients with myelofibrosis at diagnosis.

Despite a lack of consensus across the field, starting patients on treatment when they present with myelofibrosis may be optimal, Jamieson says. Historically, patients diagnosed with myelofibrosis were monitored until disease progression because treatment options were limited and ineffective, Jamieson explains.

However, in chronic myeloid leukemia (CML), initial treatment with TKIs at diagnosis have provided prolonged responses in most patients who can tolerate therapy, Jamieson says. Moreover, TKIs are generally well tolerated, so most patients can derive a substantial response, Jamieson adds.

The treatment of patients with myelofibrosis appears to be in-line with the story in CML, Jamieson says. However, it is important to complete the Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score, and understand the patients level of fibrosis, presence or absence of high-risk mutations or cytogenetics, white count, platelet, and hemoglobin levels, and transfusion-dependence status, Jamieson says. Ultimately, most patients with myelofibrosis should be treated up front when these factors are considered, Jamieson concludes.

Read more here:
Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis - OncLive

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of Julie Krop, M.D., as Chief Medical Officer. Dr. Krop will oversee all clinical development, regulatory, CMC, and medical affairs for the Companys advancing Wholly Owned Pipeline.

"We are pleased to welcome Julie to our senior leadership team as our Wholly Owned Pipeline rapidly grows and advances across multiple areas of significant patient need," said Daphne Zohar, Founder and Chief Executive Officer of PureTech. "Julie is a biopharmaceutical industry veteran with a wide breadth of expertise across multiple therapeutic areas and orphan indications. Over the course of her career, she has overseen development of eight therapeutics that advanced through Phase 3, including three FDA approvals. We believe her expertise in mid- to late-stage clinical development, in addition to her extensive experience as a board-certified physician and leader in regulatory affairs, will be important assets as we advance our lead program, LYT-100, towards potential registration-enabling development in idiopathic pulmonary fibrosis and potentially other progressive fibrosing interstitial lung diseases.

Dr. Krop joins PureTech from Freeline Therapeutics, a clinical-stage gene therapy company, where she served as Chief Medical Officer. Prior to this role, Dr. Krop served as Chief Medical Officer of AMAG Pharmaceuticals (acquired by Covis group for $647 million), where she oversaw clinical development, regulatory affairs, clinical operations, medical affairs, program management and pharmacovigilance. During her time at AMAG, Dr. Krop was responsible for the oversight of three FDA approvals. Earlier in her career, she held leadership positions at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals and Pfizer. Dr. Krop received her M.D. from Brown University School of Medicine and completed an internal medicine residency at Georgetown University Hospital. Additionally, she completed fellowships in epidemiology, clinical trial design and endocrinology as a Robert Wood Johnson Foundation Clinical Scholar at the Johns Hopkins School of Medicine.

I am thrilled to join the leadership team at PureTech during such an exciting time in the Companys growth and clinical development, said Dr. Krop. PureTechs research and development model is a truly unique approach that has fostered a broad wealth of expertise within the Company that now powers the teams innovative development efforts across multiple therapeutic candidates. I look forward to helping drive PureTechs mission and advancing an incredibly promising pipeline of investigational therapies for patients in need.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization, as of the date of PureTechs most recently filed Annual Report on Form 20-F. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit http://www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of our therapeutic candidates, our expectations regarding the appointment of our new Chief Medical Officer, and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Read the original post:
PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer - Business Wire

What is regenerative medicine?

Regenerative medicine is a new form of medicine that uses artificially processed and cultured cells or tissues to repair, regenerate, and restore certain tissue or organ functions that have been lost due to causes such as illness, accidents, or aging.

Many conditions considered hard to treat or believed to lack effective treatments (e.g., restoring brain functions of patients that have suffered brain damage from ischemic stroke, or motor functions of patients that have lost the use of their legs due to spinal cord injuries sustained in an accident) are expected to be overcome by the power of regenerative medicine in the future.

Regenerative medicine mainly uses human cells to repair and restore functions of tissues and organs. It encompasses a wide range of treatment techniques and approaches ranging from the use of microscopic cells to organ transplants.The primary cells currently being researched for applications in regenerative medicines are somatic stem cells, embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells. Stem cells can differentiate or proliferate into different types of cells, and are believed to be effective in promoting repair and regeneration of tissues or organs that have been damaged due to illness or other causes. Research on regenerative medicine using cells has been underway even before iPS cells were developed.

Professor Shinya Yamanaka, who pioneered iPS cell research, won the Nobel Prize in Physiology or Medicine for his accomplishments in 2012, paving the way for widespread research in regenerative medicine around the world. The Japanese government designated regenerative medicine as a growth industry with the enforcement of the Act on Securing Safety of Regenerative Medicine and the revised Pharmaceutical Act in 2014, marking the start of a countrywide effort to lead the world in the practical application of regenerative medicines.

Various transplants that use cell types created from human stem cells, embryonic stem (ES) cells, or induced pluripotent stem cells (iPS) cells are being planned in Japan.

The human body is said to comprise over 37 trillion individual cells belonging to over 200 cell types. Through a repeated process of cell division and proliferation, what starts out as a single fertilized egg ultimately differentiates into the full range of cells that make up the human body (such as nerve cells, cardiac muscle cells, and liver cells).

The human body is made up of both differentiated cells (somatic cells) and cells that are still differentiating (somatic stem cells). Stem cells are characterized by the capacity to self-renew or differentiate into cells that form specific tissues and organs. Somatic stem cells include hematopoietic stem cells, neural stem cells, and mesenchymal stem cells, which differentiate into a limited range of cells. For example, hematopoietic stem cells, found in large numbers in bone marrow, produce hematopoietic cells such as white blood cells and platelets, but they normally do not differentiate into other cell types.

Embryonic stem (ES) cells can differentiate into a much wider variety of cell types than somatic stem cells. They are believed to have the capacity (at least in theory) to develop into the full range of cells that make up the human body, including cardiac muscle cells, nerve cells, liver cells, and blood cells. However, because ES cells are derived from fertilized eggsin many cases from surplus embryos discarded in infertility treatmentsthe practice of using such cells for regenerative medicine has stirred debate centered on ethical concerns in many countries. In particular, the use of cells derived from aborted fetuses has drawn wide criticism on ethical grounds.

In 2007, Professor Shinya Yamanaka of Kyoto University successfully developed induced pluripotent stem (iPS) cellsa new form of pluripotent cells that is not derived from fertilized eggsfrom human skill cells. iPS cells closely resemble ES cells by virtue of their capacity to differentiate into a wide range of cells, including cardiac muscle cells, nerve cells, liver cells, and blood cells. They offer an advantage over ES cells because they eliminate the ethical concerns. However, iPS cells, like ES cells, can proliferate indefinitely, and issues such as controlling their proliferation capacity will need to be resolved before they can be used in practical applications. iPS cells are an incredible technology with tremendous potential, but it will take some time before they can be put into practical applications.

Regenerative medicine that uses somatic cells (differentiated cells) can only target a limited range of conditions, and development efforts in this field have therefore already reached a mature stage. In contrast, stem cells (which can differentiate into other cells) can be used to target a much broader range of conditions, and are therefore actively being researched around the world.

Among somatic cells, mesenchymal stem cells (MSC), which can be readily isolated and expanded from bone marrow aspirate, are a suitable cell source for regenerative medicine, and they are already used in therapeutic applications.

Among regenerative medicines, SanBio focuses on developing products for the central nervous system that are not effectively treated at the present time. Examples of these diseases include dysfunction associated with: stroke, traumatic brain injury, retinal degeneration (e.g., age-related macular degeneration), spinal cord injury, Parkinsons disease, Alzheimers disease, and others.Our products are intended to restore motor and sensory functions by inducing or promoting the innate, natural regenerative processes of patients physical functions that were lost due to diseases or accidents.

See original here:
Regenerative Medicine | SanBio - Official Site

Leading Edge Care

Regenerative medicine, also called orthobiologic therapy, works to improve the healing of injured muscles, tendons and joints. The hope is that these treatments can offer relief at a level between a more minor cartilage repair procedure and full joint replacement.

The body has a strong ability to heal itself. Two cell factors, MSCs and platelets, assist in tissue restoration and regeneration.

These cellular substances may:

MSCs, previously known as Mesenchymal stem cells, and PRP (platelet-rich plasma) are considered biologic therapy. These substances are derived from the body and are injected into the injured or diseased area, such as an injured muscle, an inflamed tendon or an arthritic joint.

Platelet rich plasma, or PRP, comes from your blood. Platelets are cells in your blood that have a lot of growth factors and anti-inflammatory agents, both of which help your body to heal.

If your body is injured, platelets are naturally delivered to the injury. The platelets will then release the substances that they hold that help encourage tissue repair. Almost all tissue injuries heal using this process.

For PRP, a sample of your blood is taken. The sample is processed to concentrate the platelets together into the plasma (a layer of your blood), which is then injected into the part of your body that needs healing. The procedure is done in an office and takes 20-30 minutes. Talk with your physician about any activities that you shouldnt do after the procedure.

MSCs can turn into multiple types of cells and tissues. If you break a bone, for example, you will need more bone cells in order to heal the fracture. MSCs are sent by your body to the fracture and grow into new bone cells to repair the break. The same process occurs if you tear a muscle or have a cut in your skin. The description is simple, but the actual process within your body is incredibly complicated.

Mesenchymal stem cells are a specific type of cell in your body. They line blood vessels, and the type used for orthobiologic injection therapy can most easily be found in bone marrow, fat, and amniotic fluid. When injected into an injured or diseased joint or tissue, they dont turn into other types of cells. Instead, they send out signals to the body to decrease inflammation, pain, and infection.

To receive MSC therapy, you will go to an office or to a procedure center.

Amniotic products are shipped frozen, thawed just before use, and are injected into the part of the body being treated.

Bone marrow products and adipose-derived (fat-derived) MSCs are taken from your body: bone marrow MSCs from the crest of your pelvic bone and adipose-derived MSCs from your belly or flank. In both cases the area is anesthetized (numbed) and a needle is placed to draw out the tissue.

The bone marrow or adipose tissue is processed to concentrate important cells and factors which are then injected into the part of the body being treated.

Adipose,or fat tissue, gives the highest amount of cells for these purposes that we know of.

Q: Which are better: PRP or MSCs?A: We dont have this answer. Research has shown that both procedures are generally effective regarding accelerated tendon healing and joint pain control.

Q: How many injections are required?A: Scientists are still studying this. Most MSC studies published used a single injection. Many PRP studies are use several injections separated by weeks or a month. Evidence has not shown for certain that multiple injections are better than a single injection yet.

Q: If I have MSCs injected into my arthritic knee, will it grow new cartilage?A: Studies have shown that areas with cartilage damage may heal better when MSCs are injected. However, the effect of orthobiologic injections is thought to be more pain control than regrowing cartilage. In a knee with arthritis, orthobiologic therapy is a potential bridge between knee restoration and a total knee replacement. You can, however, achieve significant pain control for a period of time. If you have a bone-on-bone joint, where all of the cartilage has worn away, it is very unlikely that an injection with MSCs will give you a new layer of cartilage.

Q: How long will the injection last?A: Studies have shown that the pain-controlling effects of some orthobiologic injections may last 1-2 years or longer. However, PRP studies mostly look at 6-12 month follow-up.

Q: How fast will the injection work?A: While the cells go to work immediately, the effects can take 1-2 months before you notice results. The exact amount of time varies by patient and depends on the exact amount and type of damage being treated.

Q: Which MSC preparation is best: BMAC, adipose, or amniotic?A: Scientists are still working to figure this out. For example, PRP has very effective growth factors, cytokines, and proteins, and few if any cells. Fat and bone marrow have more cells, but were not sure yet if more cells means it will work better.

Q: What does research show?A: Orthobiologic products are a hot button concept in medicine today. Orthobiologics are regularly being used in orthopedics, although we do not fully understand their definition or efficacy. However, scientific studies show good pain relief for people with arthritis and some types of tendon problems, plus quicker healing of tendon injuries with PRP and some MSC products. It could be years before we have all the answers.

Q: Are orthobiologic injections covered by insurance? How much does it cost?A: Currently most insurance policies do not cover orthobiologic injections since they are considered investigational. Speak to your physicians office about the price, which varies depending on the product and procedure used. Ask your health savings account advisor to see if these injections qualify.

Q: How do I make an appointment?A: First, you need to have a screening appointment to see if youre a candidate for these orthobiologic injections. The screening appointment may involve x-rays and an MRI. The physician will then determine if orthobiologic injections are right for you. A separate appointment will be scheduled for the actual procedure.

Excerpt from:
Regenerative Medicine | OrthoVirginia

At Mayo Clinic, an integrated team, including stem cell biologists, bioengineers, doctors and scientists, work together and study regenerative medicine. The goal of the team is to treat diseases using novel therapies, such as stem cell therapy and bioengineering. Doctors in transplant medicine and transplant surgery have pioneered the study of regenerative medicine during the past five decades, and doctors continue to study new innovations in transplant medicine and surgery.

In stem cell therapy, or regenerative medicine, researchers study how stem cells may be used to replace, repair, reprogram or renew your diseased cells. Stem cells are able to grow and develop into many different types of cells in your body. Stem cell therapy may use adult cells that have been genetically reprogrammed in the laboratory (induced pluripotent stem cells), your own adult stem cells that have been reprogrammed or developed.

Researchers also study and test how reprogrammed stem cells may be turned into specialized cells that can repair or regenerate cells in your heart, blood, nerves and other parts of your body. These stem cells have the potential to treat many conditions. Stem cells also may be studied to understand how other conditions occur, to develop and test new medications, and for other research.

Researchers across Mayo Clinic, with coordination through the Center for Regenerative Medicine, are discovering, translating and applying stem cell therapy as a potential treatment for cardiovascular diseases, diabetes, degenerative joint conditions, brain and nervous system (neurological) conditions, such as Parkinson's disease, and many other conditions. For example, researchers are studying the possibility of using stem cell therapy to repair or regenerate injured heart tissue to treat many types of cardiovascular diseases, from adult acquired disorders to congenital diseases. Read about regenerative medicine research for hypoplastic left heart syndrome.

Cardiovascular diseases, neurological conditions and diabetes have been extensively studied in stem cell therapy research. They've been studied because the stem cells affected in these conditions have been the same cell types that have been generated in the laboratory from various types of stem cells. Thus, translating stem cell therapy to a potential treatment for people with these conditions may be a realistic goal for the future of transplant medicine and surgery.

Researchers conduct ongoing studies in stem cell therapy. However, research and development of stem cell therapy is unpredictable and depends on many factors, including regulatory guidelines, funding sources and recent successes in stem cell therapy. Mayo Clinic researchers aim to expand research and development of stem cell therapy in the future, while keeping the safety of patients as their primary concern.

Mayo Clinic offers stem cell transplant (bone marrow transplant) for people who've had leukemia, lymphoma or other conditions that have been treated with chemotherapy.

Visit link:
Mayo Clinic Transplant Center - Regenerative medicine